

Filed on behalf of Patent Owner Genentech, Inc. by:

David L. Cavanaugh (Reg. No. 36,476)	Adam R. Brausa (Reg No. 60,287)
Lauren V. Blakely (Reg. No. 70,247)	Daralyn J. Durie (<i>Pro Hac Vice</i>)
Robert J. Gunther, Jr. (<i>Pro Hac Vice</i>)	DURIE TANGRI LLP
Lisa J. Pirozzolo (<i>Pro Hac Vice</i>)	217 Leidesdorff Street
Kevin S. Prussia (<i>Pro Hac Vice</i>)	San Francisco, CA 94111
Andrew J. Danford (<i>Pro Hac Vice</i>)	
WILMER CUTLER PICKERING	
HALE AND DORR LLP	
1875 Pennsylvania Ave., NW	
Washington, DC 20006	

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PFIZER, INC., AND
SAMSUNG BIOEPIS CO., LTD.,
Petitioners,

v.

GENENTECH, INC.,
Patent Owner.

Case IPR2017-01489
U.S. Patent 6,407,213

**PATENT OWNER'S FOURTH UPDATED MANDATORY NOTICES
UNDER 37 C.F.R. §42.8**

Patent Owner Genentech, Inc. hereby files fourth updated mandatory notices pursuant to 37 C.F.R. § 42.8.

I. REAL PARTY IN INTEREST

No change.

II. RELATED MATTERS

Pursuant to 37 C.F.R. § 42.8(b)(2), Patent Owner identifies the following matters that may relate to U.S. Application No. 08/146,206, which issued as U.S. Patent No. 6,407,213:

- U.S. Patent No. 6,407,213 is the patent at issue in *Samsung Bioepis Co., Ltd. v. Genentech, Inc.*, IPR2017-02140, which has been joined with this proceeding;
- U.S. Patent No. 6,407,213 is the patent at issue in *Pfizer, Inc. v. Genentech, Inc.*, IPR2017-01488, which is pending;
- U.S. Patent No. 6,407,213 is the patent at issue in *Samsung Bioepis Co., Ltd. v. Genentech, Inc.*, IPR2017-02139, which has been joined with *Pfizer, Inc. v. Genentech, Inc.*, IPR2017-01488;
- U.S. Patent No. 6,407,213 is the patent at issue in *Celltrion, Inc. v. Genentech, Inc.*, IPR2017-01373, which is pending;
- U.S. Patent No. 6,407,213 is the patent at issue in *Celltrion, Inc. v. Genentech, Inc.*, IPR2017-01374, which is pending;

- U.S. Patent No. 6,407,213 was the patent at issue in *Boehringer Ingelheim Pharmaceuticals, Inc. v. Genentech, Inc.*, IPR2017-02031, which has been terminated and adverse judgment entered; and
- U.S. Patent No. 6,407,213 was the patent at issue in *Boehringer Ingelheim Pharmaceuticals, Inc. v. Genentech, Inc.*, IPR2017-02032, which has been terminated and adverse judgment entered;
- U.S. Patent No. 6,407,213 was the patent at issue in *Mylan Pharmaceuticals Inc. v. Genentech, Inc.*, IPR2016-01693, which has been terminated;
- U.S. Patent No. 6,407,213 was the patent at issue in *Mylan Pharmaceuticals Inc. v. Genentech, Inc.*, IPR2016-01694, which has been terminated;
- U.S. Patent No. 6,407,213 is a patent at issue in *Genentech, Inc. et al. v. Pfizer, Inc.* (D. Del.) 1:17-cv-01672, which is pending;
- U.S. Patent No. 6,407,213 is a patent at issue in *Celltrion, Inc. et al. v. Genentech, Inc. et al.* (N.D. Cal.) No. 18-cv-00274, which was dismissed;
- U.S. Patent No. 6,407,213 is a patent issue in *Genentech, Inc. et al. v. Celltrion, Inc. et al.* (D. Del.) No. 18-cv-00095, which is pending;
- U.S. Patent No. 6,407,213 is a patent at issue in *Genentech, Inc. et al. v. Amgen Inc.* (D. Del.) 1:18-cv-00924, which is pending;
- U.S. Patent No. 6,407,213 is a patent at issue in *Genentech, Inc. et al. v. Celltrion, Inc. et al.* (D. Del.) 1:18-cv-01025, which is pending;

- U.S. Patent No. 6,407,213 is a patent at issue in *Genentech, Inc. et al. v. Samsung Bioepis Co., Ltd.* (D. Del.) 1:18-cv-01373, which is pending;
- U.S. Patent No. 6,407,213 is a patent at issue in *Celltrion, Inc. et al. v. Genentech, Inc. et al.* (Fed. Cir.) No. 2018-2160, which is pending;
- U.S. Patent No. 6,407,213 is a patent at issue in *Genentech, Inc. et al. v. Amgen Inc.* (D. Del.) No. 1:17-cv-01407, which is pending.
- U.S. Patent No. 6,407,213 is a patent at issue in *Amgen Inc. v. Genentech, Inc. et al.* (C.D. Cal.) No. 2:17-cv-07349, which has been dismissed.
- U.S. Patent No. 6,407,213 is a patent at issue in *Genentech, Inc. et al. v. Amgen Inc.* (D. Del.) No. 1:17-cv-01471, which is pending.

Patent Owner does not concede that any of the above-identified proceedings would affect, or be affected by, a decision in the present *inter partes* review.

III. COUNSEL

No change.

IV. SERVICE INFORMATION

No change.

Respectfully submitted,

Date: September 19, 2018

By: /David L. Cavanaugh/
David L. Cavanaugh
Registration No. 36,476

IPR2017-01489
Patent Owner's Fourth Updated Mandatory Notices

WILMER CUTLER PICKERING HALE AND DORR LLP
1875 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20006
TEL: 202-663-6025
FAX: 202-663-6363
EMAIL: david.cavanaugh@wilmerhale.com

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.